Abstract:Doxorubicin (Dox) is an effective anti-cancer agent, whose clinical use is limited by the cytotoxicity in non-target tissues, especially the heart and brain. The drug-induced neuronal damage is primarily mediated by oxidative stress, in which autophagy plays a central role. Although numerous studies indicate the involvement of autophagy in neurodegenerative diseases and brain injury, the evidence concerning autophagic process in Dox-induced neuronal death is limited. We found that repeated Dox administration induced the protein expression of LC3II and P62 and impaired autophagic flux with enhanced autophagasome accumulation in rat hippocampus, whereas two weeks after the cessation of Dox treatment, the autophagic process was restored, even stimulated, with normalized protein levels of LC3II and P62 and enhanced expression of Becline-1, indicating a compensatory response in the recovery state. Likewise, while repeated Dox exposure inhibited the hippocampal expression of lysosomal-associated membrane protein 2 (LAMP2) and cathepsin D (CTSD), and suppressed CTSD activity, the Dox-induced impaired autophagy-lysosome pathway was also restored in rats following two weeks of recovery. To further verify the role of autophagy, the autophagy inhibitor, 3-methyladenine (3-MA), was administrated daily for the two weeks of recovery period. Our data demonstrated that while the animals in the recovery state showed a significant trend to decreased oxidative damage, normalized antioxidative system and ameliorated endoplasmic reticulum (ER) stress compared with Dox-induced toxic model, 3-MA treatment abrogated the recovering process, resulting in sustained oxidative and ER stress and neuronal apoptosis. Collectively, the present study firstly provided the evidence for the involvement of autophagy in both development and recovery of Dox-induced neurotoxicity, highlighting a novel target for mitigating the chemotherapy-induced neuronal damage.

NAD+ Induces Autophagy of Neuro2a Cells by Increasing Oxidative Stress

NAD+ Treatment Induces Delayed Autophagy in Neuro2a Cells Partially by Increasing Oxidative Stress

NAD+ Can Induce Autophagy of Neuro2a Cells and PC12 Cells

NAD+ Treatment Decreases Tumor Cell Survival by Inducing Oxidative Stress.

NAD+ Treatment Can Prevent Multiple Rotenone‐induced Apoptotic Changes of PC12 Cells

NAD depletion mediates cytotoxicity in human neurons with autophagy deficiency

Nad+ Induces C6 Glioma Cell Death by Generating Oxidative Stress and Increasing Intracellular Calcium Concentrations

NAD+ Treatment Can Block Rotenone‐induced Nuclear Apoptotic Changes of PC12 Cells

NAD+ Treatment Induces Tumor Cell Necrosis by P2X7 Receptor‐Independent Pathways

NAD+ treatment can increase directly the antioxidant capacity of rotenone-treated differentiated PC12 cells

NAD+ Treatment Can Prevent Rotenone-Induced Increases in DNA Damage, Bax Levels and Nuclear Translocation of Apoptosis-Inducing Factor in Differentiated PC12 Cells

Nadh Can Induce Necrosis of C6 Glioma Cells and Neuro2a Cells

Regulation of the Ischemia-Induced Autophagy-Lysosome Processes by Nitrosative Stress in Endothelial Cells.

NAD+ Treatment Prevents Rotenone-Induced Apoptosis and Necrosis of Differentiated PC12 Cells

NAD(+) Administration Decreases Ischemic Brain Damage Partially by Blocking Autophagy in a Mouse Model of Brain Ischemia.

Stimulation of autophagy prevents amyloid-β peptide-induced neuritic degeneration in PC12 cells.

SIRT2, ERK and Nrf2 Mediate NAD+ Treatment-Induced Increase in the Antioxidant Capacity of PC12 Cells under Basal Conditions

Ginsenosides Rg1 and Rg2 Activate Autophagy and Attenuate Oxidative Stress in Neuroblastoma Cells Overexpressing Aβ(1-42)

Targeting the autophagy-NAD axis protects against cell death in Niemann-Pick type C1 disease models

The involvement of autophagic flux in the development and recovery of doxorubicin-induced neurotoxicity

Exogenous NAD + decreases oxidative stress and protects H 2 O 2 -treated RPE cells against necrotic death through the up-regulation of autophagy